Sharemaestro Newsreel

Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial

Novartis AG (NYSE:NVS) has discontinued development of VHB937, also known as lifonebart, after the experimental ALS drug failed to meet both its primary and secondary endpoints in a Phase II trial involving 251 patients with early-stage ALS. The drug targeted TREM2, a protein involved …

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

Novartis NVS announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has issued a positive opinion recommending marketing authorization for an additional indication of its arthritis drug Cosentyx (secukinumab). The CHMP recommended Cosentyx for the treatment …

Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations

Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Melexis: update on the share buy-back program

Melexis N.V. Press release - Regulated Information Melexis: update on the share buy-back program Ieper, Belgium – 21 September 2026, 17.45 hrs CET Melexis reports the purchase of 14,519 Melexis shares on Euronext Brussels in the period from 14 September 2026 to 18 September …

Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash

Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts. Continue Reading

Evercore ISI Adjusts Price Target on Realty Income to $65 From $68, Maintains In Line Rating

BMO Capital Adjusts Price Target on Realty Income to $66 From $68, Keeps Market Perform Rating

Realty Income or Agree Realty During a REIT Sell-Off?

The average real estate investment trust (REIT) has fallen roughly 8% over the past three months, as of this writing. Realty Income (NYSE:O), the largest net-lease REIT, is down 14%, and Agree Realty (NYSE:ADC), a smaller, faster-growing peer, is off by 16%. The main …

How Much Do You Need Invested to Cover a $2,150 Mortgage Payment With Dividends Alone?

Quick Read Covering $25,800 in annual mortgage payments with dividends requires anywhere from $258,000 to $737,000 depending on which yield tier you target. A blended portfolio yielding 5.3% and requiring roughly $482,000 outperforms pure high-yield or pure Treasury strategies by surviving multiple market cycles …

What does the EU have that the U.S. does not?

Investing.com -- European assets may offer investors advantages that are being overlooked as markets remain heavily focused on U.S. technology leadership, according to Macquarie Global Strategy, which sees structural changes supporting stronger European returns. Still guessing which names to buy? Our AI rebuilds its …

Edison (BIT:EDNR) Shares Dropped, So What Is Driving Attention Now?

Edison (BIT:EDNR) traded at €1.894 at the last close, with the share price lower over the past day, week, month, past 3 months and year to date. That recent slide in Edison's share price adds to a weaker short term trend, although the 1-year …

Simon Property (SPG) Group Raised Its Outlook Again

On August 10, Simon Property Group (NYSE:SPG) reported results for the three months through June 30 and raised its full-year profit outlook once again. Real estate funds from operations (FFO), a cash-flow measure suited to landlords, hit $3.29 per share. Tenants are earning more …

Novartis (SWX:NOVN) Takes Full Control Of A Brain Delivery Platform

Novartis (SWX:NOVN) agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed to transport therapeutics across the blood brain barrier. The transaction expands Novartis' toolkit for research into central nervous …

Gossan Resources Announces Changes to Board and Management

WINNIPEG, MB / ACCESS Newswire / September 18, 2026 / Gossan Resources Limited (GSS-TSX.V)(GSR-Frankfurt/Freiverkehr & Xetra) (the "Company" or "Gossan") is pleased to announce that the Board of Directors has appointed Kevin Norberg as interim Chief Executive Officer and Director, effective September 18, 2026. …

This Montly Dividend Stock’s 136th Dividend Hike Highlights its Long-Term Income Track Record

Realty Income Corporation (NYSE:O) has raised its monthly dividend once again, lifting the payout to $0.2715 per share from $0.2710. The new dividend is scheduled to be paid on October 15, 2026, to shareholders of record as of September 30. It is the company's …

4 Biotech Stocks to Watch as Potential Takeover Targets

M&A activity in the biotech sector has accelerated sharply in 2026, as large drugmakers increasingly turn to external innovation to strengthen pipelines, expand into new therapeutic areas and gain access to promising technologies and late-stage assets. For some companies, looming patent expirations are also …

Theranostics Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)

Company Logo The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceutical therapies. Oncology leads adoption, while therapeutic agents and radiotheranostics are key growth segments. North America holds the largest …

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Novartis Pharma AG If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹ Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; …

3 High-Yield Dividend Stocks I'd Buy in September With No Hesitation

High-yield dividend stocks can look tempting, but a big yield sometimes signals that investors expect weaker earnings or even a dividend cut. That makes the cash behind the payout more important than the yield itself. Still, three names stand out this month: Altria (NYSE: …

Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years

On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1. It marked the company's third clinical setback …

A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too

On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can …

Realty Income (O) Announces €528M Partner Investment. Can it Lift Returns?

Realty Income Corporation (NYSE:O) announced on September 14 a European property venture in which capital accounts advised by KKR & Co. Inc. (NYSE:KKR) intend to invest €528 million for a 49% interest. Closing is expected September 30, subject to customary conditions. Realty Income Corporation …

This Stock Pays a Dividend Every Single Month. Inside a Roth IRA, the IRS Never Taxes a Single One of Those Payments.

Quick Read Realty Income (NYSE: O) pays 12 monthly dividends yearly, currently $0.2715/share, yielding 5.40%. Roth IRA holders owe $0 federal tax on every payment. A $500,000 position generates $27,000 annually, costing a 37% bracket investor nearly $10,000 in federal taxes that a Roth …

Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial

On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce heart attacks, strokes and related cardiovascular events in the Lp(a)HORIZON trial, which …

Want $1,500 In Passive Income? Invest $5,000 In Each of These 4 Dividend Stocks

Quick Read A $20,000 split across Realty Income (O) and NNN REIT (NNN) yields 5.53% and 5.74%, generating $277 and $287 annually. Gladstone Commercial (GOOD) and Hercules Capital (HTGC) supercharge the portfolio with 9.43% and 10.65% yields, pushing total income to $1,568. Hercules Capital's …

Mizuho Adjusts Price Target on Realty Income to $61 From $66, Keeps Neutral Rating

RAMSAY SANTE Group unveils "Connecting Care 2030"

RAMSAY SANTE PRESS RELEASE Paris, 17 September 2026 Ramsay Santé Group unveils "Connecting Care 2030" to drive next phase of profitable growth and create long term value for all stakeholders "Connecting Care 2030", Ramsay Santé Group's new strategic roadmap, leverages the transformation achieved through …

Simon Property Group (SPG) Plans To Hand Back Square One Mall

Simon Property Group (NYSE: SPG) is reportedly preparing to hand back the Square One Mall in Saugus to its lender. The enclosed regional mall is classified as a Class C property, reflecting weaker tenant quality and softer shopper traffic than higher tier centers. Refinancing …

How to Build $8,700 a Month in Dividend Income Without Selling a Single Share

Critics Warn of AI-Driven Disaster. Anthropic and Novo Are Betting on the Opposite.

Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process. Continue Reading

Trialynx Wins Forge’s DPHARM Idol Disrupt 2026

Forge BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- This morning, Trialynx was announced as the winner of DPHARM Idol Disrupt at the 16th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 2026 event. DPHARM is a part of Forge's Fierce Life Sciences. "DPHARM Idol …

TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry

TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart. Continue Reading

Changes in the Suominen Leadership Team

Suominen Corporation Suominen Corporation's stock exchange release on September 16, 2026 at 6:30 p.m. (EEST) Changes in the Suominen Leadership Team As we continue to transform Suominen and strengthen our performance, we are further developing the capabilities and ways of working needed to execute …

Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares

Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease. Continue Reading

Changes to Suominen Corporation’s share-based incentive plans for management and key employees and to the President & CEO’s share-based signing bonus and annual share reward

Suominen Corporation Suominen Corporation's stock exchange release, September 16, 2026 at 17:00 (EEST) Changes to Suominen Corporation's share-based incentive plans for management and key employees and to the President & CEO's share-based signing bonus and annual share reward The Board of Directors of Suominen …

How a Roth IRA Can Keep Thousands More of Your High-Yield Dividend Income Compounding

Quick Read Altria (MO) and Realty Income (O) held in a taxable account at the 24% bracket cost investors $9,600 annually on a $500,000 position yielding 8%. BDCs like Main Street Capital (MAIN) are top Roth candidates because their distributions are taxed at ordinary …